Anti-magic pills
Commercial- Indications
- Magic sensitivity
Company intelligence / Profile preview
Savant Pharm
Arroyito, Córdoba, Argentinaadventurers-of-arcadia.fandom.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Commercial
01
Overview
Developing a novel anti-addiction medicine that is an antagonist to a nicotinic receptor in the brain's reward centers affecting dopamine regulation. Also developing drugs for Leishmaniasis and Chagas disease[2].
- Therapeutic areas
- PsychiatryInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
InHale Therapeutics
Beyond the preview
Go deeper on Savant Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Savant Pharm.